ChemoCentryx

CCXI NASDAQ
8.81
+0.47
+5.64%
交易中 15:38 06/17 EDT
开盘
8.67
昨收
8.34
最高
8.88
最低
8.45
成交量
24.35万
成交均量(3M)
58.94万
52周最高
14.98
52周最低
8.06
换手率
0.42%
市值
5.11亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供ChemoCentryx CCXI股票价格,ChemoCentryx股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
展开 >

最近浏览

名称
价格
涨跌幅